share_log

Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54

Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54

Evercore ISI集團維持對avidity biosciences的跑贏大盤評級,將價格目標上調至54美元。
Benzinga ·  08/12 10:04  · 評級/大行評級

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price target from $45 to $54.

Evercore ISI集團分析師Josh Schimmer維持對Avidity Biosciences(納斯達克:RNA)的跑贏大市評級,並將目標股價從45美元升至54美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論